0DL.F - Biosynex SA

Frankfurt - Frankfurt Delayed Price. Currency in EUR
9.38
+0.09 (+0.97%)
At close: 04:12PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close9.29
Open9.39
Bid9.33 x N/A
Ask9.51 x N/A
Day's Range9.38 - 9.39
52 Week Range6.79 - 18.96
Volume100
Avg. Volume3
Market Cap97.101M
Beta (5Y Monthly)-2.12
PE Ratio (TTM)5.90
EPS (TTM)1.59
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 16, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0DL.F

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

      Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The comp

    • GlobeNewswire

      Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

      STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasd

    • Benzinga

      French Rapid Testing Company Scoops Up Chembio Diagnostics For $17M

      Privately held Biosynex SA has agreed to acquire Chembio Diagnostics Inc (NASDAQ: CEMI) for $0.45 per share in an all-cash transaction valued at $17.2 million. The acquisition combines two rapid diagnostic test companies. Chembio, based in the U.S., focuses on infectious disease assays. Biosynex, based in France, provides a diversified portfolio of rapid tests covering different market segments, including infectious disease and women's health tests, Point of Care devices, and molecular diagnosti

    • GlobeNewswire

      Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

      Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide Synergistic Cost Savings STRASBOURG, France and HAUPPAUGE, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and Chembio Diagnostics, Inc. (“Chembio”) (Nasdaq: CEMI), a leading point-of-care diagnos